Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.

about

Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.

Item

http://www.wikidata.org/entity/Q38657787

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.

@en

type

Item

label

Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.

@en

prefLabel

Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.

@en

P1476

Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.

@en

P2093

Hideyuki Akaza

http://www.w3.org/2001/XMLSchema#string

Yoshiko Umeyama

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Shibasaki

http://www.w3.org/2001/XMLSchema#string

P2860

The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma

Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Cancer statistics, 2016

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

P304

1839-1852

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0104

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28707479

http://www.w3.org/2001/XMLSchema#string